# Zymeworks Inc. (ZYME) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $29.19, market value $2.1 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Zymeworks Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 0.75**. A PEG of 0.75 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 56.2×**. Each dollar of revenue is priced at 56.2×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 25.9×**. The shares trade at 25.9× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -5.8%** (5-yr avg -5.2%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -419.0%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -76.6%**. The company reported a net loss over the last twelve months.
- **Return on equity: -30.2%**. Return on equity is negative because earnings are negative.
- **Return on assets: -43.3%**. Each dollar of assets produces -43.3% of profit.

## Growth
- **Revenue growth (1 yr): 38.9%** (3-yr -36.4%/yr, 5-yr 22.2%/yr). Revenue grew 38.9% over the last year, against 22.2% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 33.3%**. Earnings per share rose 33.3%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 5.88** (quick 5.88). Current assets cover the next year's liabilities 5.88 times.
- **Altman Z-score: 17.28**. A Z-score of 17.28 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Zymeworks Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (12 analysts). 12 analysts cover Zymeworks Inc.; the consensus is strong_buy, with an average price target of $41.75 (+43% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 107.3%** (YTD 10.9%, 3-mo 21.4%). The shares are up 107.3% over twelve months including dividends.
- **From 52-week high: -6.9%** (96.2% above the low). Trading 7% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 60**. An RSI of 60 is neutral.
- **Beta (1 yr): 0.74** (volatility 54%). Beta of 0.74 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ZYME · Page: https://foliofundamentals.com/stocks/zyme

Not investment advice.